Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer

Key Points

• Treatment progression varies significantly based on homologous recombination repair mutations and race, indicating potential disparities.
• Key evidence shows 20% of patients had HRR mutations, and those mutations were linked to treatment responses.
• Analysis explored next-generation sequencing data to assess the impact of genetic mutations on treatment outcomes.
• Highlighting the need for tailored approaches in managing prostate cancer treatment, especially in racially diverse populations.